Pulmonx Corporation Common Stock (LUNG) Stock
Key stats
- Market cap
- $129.78M
- Price / Earnings ratio
- -2.9x
- EPS (TTM)
- -$1.01
- Volume
- Loading
- 52-week high
- $3.25
- 52-week low
- $1.13
Source: third-party data provider, as of November 13, 2026
Compare with LUNG
Recent news

All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
LUNG

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
LUNG

What Pulmonx (LUNG) Said on Its Q3 Earnings Call
What Pulmonx (LUNG) Said on Its Q3 Earnings Call
LUNG

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
LUNG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.90
- MACD 12/26/9
- 0.24
- EMA 9 of MACD
- 0.20
- MACD histogram
- 0.05
- SMA 50
- $2.11
- Price above SMA 50
- EMA 50
- $2.21
- Price above EMA 50
- SMA 200
- $1.69
- Price above SMA 200
- EMA 200
- $1.86
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
LUNG

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
LUNG

What Pulmonx (LUNG) Said on Its Q3 Earnings Call
What Pulmonx (LUNG) Said on Its Q3 Earnings Call
LUNG

Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
LUNG

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year
LUNG

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
LUNG

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
LUNG
News tone: automated (AI) classification of the article's content, not a price prediction.
About Pulmonx Corporation Common Stock
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Glendon E. French | CEO, President & Director | 1962 |
| Dr. Derrick Sung Ph.D. | CFO & COO | 1973 |
| Mr. David A. Lehman J.D. | General Counsel & Secretary | 1961 |
| Mr. Srikanth Radhakrishnan | Chief Science & Technology Officer | 1973 |
| Ms. Marcee M. Maroney | Vice President of Marketing | 1970 |
| Mr. Jérôme Erath | Senior VP & GM of International | — |
| Mr. Geoffrey Beran Rose | Chief Commercial Officer | 1974 |
| Dr. Narinder S. Shargill Ph.D. | Senior Vice President of Global Medical & Clinical Affairs | 1955 |
| Mr. John B. McKune | VP of Finance & Corporate Controller | 1976 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.90
- MACD 12/26/9
- 0.24
- EMA 9 of MACD
- 0.20
- MACD histogram
- 0.05
- SMA 50
- $2.11
- Price above SMA 50
- EMA 50
- $2.21
- Price above EMA 50
- SMA 200
- $1.69
- Price above SMA 200
- EMA 200
- $1.86
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $4.00
- High
- $4.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.3 | -14.7 | +57.6 | +8.5 |



